Yang YS, et al. - This research was formulated in order to investigate the effects of angiotensin receptor blockers (ARB) on insulin secretion in hypertensive patients with type 2 diabetes. A rise was noted in the late-phase glucose-stimulated insulin secretion due to fimasartan than amlodipine in subjects with type 2 diabetes and hypertension. Hence, ARB possibly appeared to be more favorable for such patients compared to other classes of anti-hypertensives.